Scuttlebutt

Scuttlebutt

Home
Notes
Chat
📰 Editions
🧭 Topics
🎙️ Sources
🗣️ People
📈 Investments
💡 Themes
Archive
About

Tempus AI - $TEM

Tempus AI CEO on its data arm: "it would probably trade at 20 or 30 or 40 times revenue"
10 takeaways: why Tempus is buying Personalis for $1.5B to enter MRD testing, what "mowing 8,000 lawns" means for its data moat, and why AI has helped…
6 hrs ago • Scuttlebutt
AI could cut the cost of developing a drug by as much as 75% — ARK Invest
11 insights: why cancer-test data now rivals the internet as AI training material, how Twist Bioscience became an Anthropic supplier, and a $2–3M…
Sep 29 • Scuttlebutt
Eric Lefkofsky: the Merck-Moderna drug is a vaccine built for one patient
5 insights: What the skin-cancer headlines left out, why he says health care is the biggest eventual beneficiary of AI, and what 23 years since the…
Sep 15 • Scuttlebutt
© 2026 The Golden Age LLC · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.